Hormonal
Caloric restriction (CR) extends lifespan and delays aging-related diseases in mammals by reversing age-associated aberrant DNA methylation patterns and activating SIRT1-mediated histone deacetylation.
Caloric restriction, defined as reducing total calorie intake by 25-60% while ensuring all essential nutrients are consumed, is the most effective known environmental intervention for extending lifespan in animal models. It works by triggering epigenetic changes, specifically reversing age-related DNA methylation errors and activating SIRT1, which improves genomic stability and delays disease onset. While direct long-term human lifespan data is lacking, short-term human studies show CR improves metabolic markers like glucose homeostasis and blood pressure.
Caloric restriction (CR) is by far the most effective environmental manipulation that can extend maximum lifespan in many different species... CR is speculated to exert its aging-delaying effect through its capacity to increase genomic stability. Reversal of aberrant DNA methylation during aging is believed to be the most effective mechanism for CR to maintain chromatin function and subsequently influence aging processes.
Why this rating
The paper is a review of animal models (rodents, yeast, flies) and in vitro studies; human data is limited to short-term metabolic markers and observational associations, not long-term lifespan trials.
Source
Epigenetic regulation of caloric restriction in aging
Yuanyuan Li et al. · BMC Medicine · 2011
DOI 10.1186/1741-7015-9-98
More from this paper
- Caloric restriction prevents or delays the onset of specific aging-related diseases, including cancer, diabetes, cardiovascular disease, and neurodegenerative disorders, in rodents and nonhuman primates.Moderate
- Caloric restriction extends lifespan in humans by modulating epigenetic markers, specifically through DNA hypermethylation of the p16INK4a gene promoter and SIRT1-mediated deacetylation.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →